Pharmaceuticals, Biotechnology and Life Sciences
Eli Lilly and Company has announced that psoriatic arthritis (PsA) patients treated with ixekizumab for 24 weeks achieved significant improvements…
Sanofi and Regeneron Inc. have announced results from a pivotal Phase 3 study of sarilumab, an investigational, human antibody against…
Novartis has announced new results for Cosentyx (secukinumab) showing no further progression in joint damage in 84% of patients with…
Eli Lilly and Company and Incyte Corporation have announced detailed data from the pivotal phase 3 RA-BEGIN study, which show…
AstraZeneca has entered into a definitive agreement to acquire Nasdaq-listed ZS Pharma, a biopharmaceutical company based in San Mateo, California.
FDA has approved Genvoya, a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide.
Sanofi and Lexicon Pharmaceuticals have entered into a collaboration and license agreement for the development and commercialization of sotagliflozin, an investigational new oral dual inhibitor of sodium-glucose cotransporters 1 and 2 (SGLT-1 and SGLT-2), which could be a potential treatment option for people with diabetes.
Johnson & Johnson has announced a definitive agreement to acquire Novira Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company developing novel therapies for curative treatment of chronic hepatitis B virus (HBV) infection.
Colonis, part of Quantum Pharma’s newly formed Niche Pharmaceuticals division, has launched its in-licensed range of patented medical devices to treat…
Sanofi and Hanmi Pharmaceutical Co., Ltd. announced Thursday a worldwide license agreement to develop a portfolio of experimental, long-acting diabetes treatments.